JP2005520814A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520814A5
JP2005520814A5 JP2003564015A JP2003564015A JP2005520814A5 JP 2005520814 A5 JP2005520814 A5 JP 2005520814A5 JP 2003564015 A JP2003564015 A JP 2003564015A JP 2003564015 A JP2003564015 A JP 2003564015A JP 2005520814 A5 JP2005520814 A5 JP 2005520814A5
Authority
JP
Japan
Prior art keywords
fluorophenyl
phenyl
ethyl
heptenoic acid
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003564015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520814A (ja
JP4524111B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/000954 external-priority patent/WO2003064392A1/en
Publication of JP2005520814A publication Critical patent/JP2005520814A/ja
Publication of JP2005520814A5 publication Critical patent/JP2005520814A5/ja
Application granted granted Critical
Publication of JP4524111B2 publication Critical patent/JP4524111B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003564015A 2002-01-31 2003-01-30 HMG−CoA還元酵素阻害剤の製造法 Expired - Lifetime JP4524111B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31
PCT/EP2003/000954 WO2003064392A1 (en) 2002-01-31 2003-01-30 Process for the manufacture of hmg-coa reductase inhibitors

Publications (3)

Publication Number Publication Date
JP2005520814A JP2005520814A (ja) 2005-07-14
JP2005520814A5 true JP2005520814A5 (https=) 2006-03-09
JP4524111B2 JP4524111B2 (ja) 2010-08-11

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564015A Expired - Lifetime JP4524111B2 (ja) 2002-01-31 2003-01-30 HMG−CoA還元酵素阻害剤の製造法

Country Status (22)

Country Link
US (2) US7371865B2 (https=)
EP (1) EP1472228B1 (https=)
JP (1) JP4524111B2 (https=)
KR (1) KR20040081161A (https=)
CN (1) CN1305853C (https=)
AT (1) ATE426594T1 (https=)
AU (1) AU2003226971B2 (https=)
BR (1) BR0307303A (https=)
CA (1) CA2472776C (https=)
CO (1) CO5601005A2 (https=)
DE (1) DE60326819D1 (https=)
EC (1) ECSP045214A (https=)
ES (1) ES2323267T3 (https=)
IL (1) IL162980A (https=)
MX (1) MXPA04007396A (https=)
NO (1) NO327091B1 (https=)
NZ (1) NZ534232A (https=)
PL (1) PL370658A1 (https=)
PT (1) PT1472228E (https=)
RU (1) RU2299196C2 (https=)
WO (1) WO2003064392A1 (https=)
ZA (1) ZA200405322B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
CN100408562C (zh) * 2003-04-24 2008-08-06 大赛璐化学工业株式会社 (3r,5s,6e)-7-[2-环丙基-4-(4-氟苯基)喹啉-3-基]-3,5-二羟基-6-庚烯酸乙酯的制备方法
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
WO2006035286A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US7687660B2 (en) * 2007-04-18 2010-03-30 Teva Pharmaceutical Industries Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
US8487105B2 (en) * 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en) * 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
EP2383260A3 (en) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
JP5822169B2 (ja) * 2010-07-01 2015-11-24 ユーハン・コーポレイションYUHAN Corporation HMG−CoA還元酵素阻害剤及びその中間体の製造方法
EP3178812A1 (en) * 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
EP2785851A2 (en) 2011-11-28 2014-10-08 Mylan Laboratories, Limited Process for producing chiral statin side chain intermediates employing candida antarctica lipase b
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
DK0484614T3 (da) * 1990-05-11 1995-06-12 American Cyanamid Co N-Acylerede arylpyrroler, der kan anvendes som insekticide, akaricide, nematodicide og molluscicide midler
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
KR100883874B1 (ko) * 2001-02-02 2009-02-17 미쯔비시 가가꾸 가부시끼가이샤 (3r,5s)-(e)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법
EP1466905B1 (en) * 2001-11-14 2011-05-18 Nissan Chemical Industries, Ltd. Process for producing optically active oxoheptenoic acid ester
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Similar Documents

Publication Publication Date Title
JP2005520814A5 (https=)
CA2472776C (en) Process for the manufacture of hmg-coa reductase inhibitors
US20100056793A1 (en) Process for pure montelukast sodium through pure intermediates as well as novel amine salts
CA2255333C (en) Quinolinone derivative, method for preparing the same, and anti-allergic agent
RU2360903C2 (ru) Способ получения органических соединений
AU2003226971A1 (en) Process for the manufacture of HMG-CoA reductase inhibitors
JP2005516064A5 (https=)
JP2014031374A (ja) キノリン類化合物及びその薬物組成物、製造方法並びに応用
EP1954679B1 (en) A new intermediate for making montelukast and related compounds
US6284888B1 (en) Vinyl-ACA purification process
WO2014051077A1 (ja) 高純度の含窒素複素環化合物の製造方法
EP2598485B1 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
JP5533654B2 (ja) 3,5−ジヒドロキシ−6−ヘプテン酸アミン塩類の製造方法
JP3481325B2 (ja) 光学活性な3−オキシ−5−オキソ−6−ヘプテン酸誘導体の製法
AU683481B2 (en) Quinoline compounds
EP0070013B1 (en) Oral absorption enhancement of carboxylic acid pharmaceuticals using (5-alkyl-2-oxo-1,3-dioxolen-4-yl)methyl ester group
WO2002098859A1 (en) Process for preparation of a quinolinecarbaldehyde
JPS59199693A (ja) インドリルグリシルセフアロスポリン誘導体
SK13582001A3 (sk) Spôsob prípravy kyseliny 3S-3-amino-3-arylpropiónovej a jej derivátov
KR960011778B1 (ko) 신규한 결정성 세팔로스포린 유도체의 제조방법
RU2002744C1 (ru) Способ получени 1-замещенной 6-фтор-4-оксо-7-(1-пиперазинил)-1,4-дигидрохинолин-3-карбоновой кислоты
FI60210C (fi) Foerfarande foer framstaellning av 7beta-acylamido-cefalosporansyraesterfoereningar
KR101868618B1 (ko) (5-히드록시-4-옥소-4h-피란-2-일)메틸(2e)-3-(1,3-벤조디옥솔-5-일)아크릴레이트 화합물의 신규 제조 방법 및 이에 사용되는 신규 중간체
JPH0794452B2 (ja) 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩
KR20220132383A (ko) L,d-엘도스테인의 개별적 합성방법